SCNX - Scienture Holdings, Inc.

SCNX - Scienture Holdings, Inc.

https://scienture.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding

GlobeNewswire • 1 month, 3 weeks ago • score: 0.42

Commack, NY, July 24, 2025 ( GLOBE NEWSWIRE ) -- SCIENTURE HOLDINGS, INC. ( NASDAQ: SCNX ) ( the "Company" ) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to ...

Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements

GlobeNewswire • 1 month, 4 weeks ago • score: 0.37

Commack, NY, July 16, 2025 ( GLOBE NEWSWIRE ) -- SCIENTURE HOLDINGS, INC. ( NASDAQ: SCNX ) ( the "Company" ) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to ...

SCIENTURE Announces Executive Leadership Transition

Business Insider • 3 months, 3 weeks ago • score: 0.37

TAMPA, FL, May 22, 2025 ( GLOBE NEWSWIRE ) -- SCIENTURE HOLDINGS, INC. ( NASDAQ: SCNX ) ( the "Company" ) , a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to ...

SCIENTURE Announces Executive Leadership Transition

GlobeNewswire • 3 months, 3 weeks ago • score: 0.31

TAMPA, FL, May 22, 2025 ( GLOBE NEWSWIRE ) -- SCIENTURE HOLDINGS, INC. ( NASDAQ: SCNX ) ( the "Company" ) , a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to ...

SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, ( losartanpotassium ) Oral Suspension, 10mg/mL.

Business Insider • 3 months, 3 weeks ago • score: 0.31

SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL.

SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, ( losartan potassium ) Oral Suspension, 10mg/mL for a target product launch in July 2025.

Business Insider • 4 months, 3 weeks ago • score: 0.36

SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

None

52W High

$9.55

52W Low

$0.69

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

N/A

Valuation

Fair

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

1.74

Forward P/E (<15 better)

21.83

EV/EBITDA (<8 favorable)

-1.57

EV/Revenue (<3 favorable)

165.84

P/S (TTM) (<3 favorable)

133.80

P/B (<3 favorable)

0.22

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

25.78%

Institutions (25–75% balanced)

1.56%

Shares Outstanding

19,356,200

Float

12,569,100

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

2024-07-19

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

128,200

Gross Profit (TTM)

7,380

EPS (TTM)

0.51

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-128.25%

ROE (TTM) (>15% strong)

-0.54%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.84

Momentum

Bearish momentum

Value

-0.2141

Previous

-0.2307

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025